Goldberg RB - Search Results

1

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.

Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M. Crandall JP, et al. Among authors: goldberg rb. BMJ Open Diabetes Res Care. 2017 Oct 10;5(1):e000438. doi: 10.1136/bmjdrc-2017-000438. eCollection 2017. BMJ Open Diabetes Res Care. 2017. PMID: 29081977 Free PMC article.

2

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators. Goldberg RB, et al. Diabetes Care. 2005 Jul;28(7):1547-54. doi: 10.2337/diacare.28.7.1547. Diabetes Care. 2005. PMID: 15983299 Clinical Trial.

3

Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program.

Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, Hanson RL, Shuldiner AR, Knowler WC, Altshuler D, Florez JC; Diabetes Prevention Program Research Group. Moore AF, et al. Diabetes. 2008 Sep;57(9):2503-10. doi: 10.2337/db08-0284. Epub 2008 Jun 10. Diabetes. 2008. PMID: 18544707 Free PMC article.

4

Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.

Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, Fowler SE, Mather K, Marcovina S, Saudek C, Matulik MJ, Price D; Diabetes Prevention Program Research Group. Goldberg RB, et al. Diabetes Care. 2009 Apr;32(4):726-32. doi: 10.2337/dc08-0494. Epub 2009 Jan 26. Diabetes Care. 2009. PMID: 19171717 Free PMC article. Clinical Trial.

5

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial.

Ratner RE, Rosenstock J, Boka G; DRI6012 Study Investigators. Ratner RE, et al. Diabet Med. 2010 Sep;27(9):1024-32. doi: 10.1111/j.1464-5491.2010.03020.x. Diabet Med. 2010. PMID: 20722676 Free PMC article. Clinical Trial.

6

Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study.

Rubin RR, Ma Y, Peyrot M, Marrero DG, Price DW, Barrett-Connor E, Knowler WC; Diabetes Prevention Program Research Group. Rubin RR, et al. Diabetes Care. 2010 Dec;33(12):2549-51. doi: 10.2337/dc10-1033. Epub 2010 Aug 30. Diabetes Care. 2010. PMID: 20805256 Free PMC article. Clinical Trial.

7

Menopause and risk of diabetes in the Diabetes Prevention Program.

Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E; Diabetes Prevention Program Research Group. Kim C, et al. Menopause. 2011 Aug;18(8):857-68. doi: 10.1097/gme.0b013e31820f62d0. Menopause. 2011. PMID: 21709591 Free PMC article. Clinical Trial.

8

TCF7L2 polymorphism, weight loss and proinsulin:insulin ratio in the diabetes prevention program.

McCaffery JM, Jablonski KA, Franks PW, Dagogo-Jack S, Wing RR, Knowler WC, Delahanty L, Dabelea D, Hamman R, Shuldiner AR, Florez JC; Diabetes Prevention Program Research Group. McCaffery JM, et al. PLoS One. 2011;6(7):e21518. doi: 10.1371/journal.pone.0021518. Epub 2011 Jul 26. PLoS One. 2011. PMID: 21814547 Free PMC article.

9

Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.

Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, Kahn SE, Knowler WC, Florez JC, Franks PW; Diabetes Prevention Program Research Group. Delahanty LM, et al. Diabetes Care. 2012 Feb;35(2):363-6. doi: 10.2337/dc11-1328. Epub 2011 Dec 16. Diabetes Care. 2012. PMID: 22179955 Free PMC article. Clinical Trial.

10

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Perreault L, et al. Lancet. 2012 Jun 16;379(9833):2243-51. doi: 10.1016/S0140-6736(12)60525-X. Epub 2012 Jun 9. Lancet. 2012. PMID: 22683134 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

365 results

Search Page

Filters